The trial will evaluate the safety and efficacy of single-agent carfilzomib in patients with recurrent or advanced solid tumors. Subjects will be enrolled and stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer.
The open-label, multi-center clinical trial is a two-stage design, with pre-determined criteria for continuation after an initial cohort of patients have been treated. Patients enrolled in the study will receive carfilzomib twice a week for three weeks with a one week rest period.
Lori Kunkel, chief medical officer of Proteolix, said: “Carfilzomib exhibits a highly selective mechanism of action for the proteasome, an important therapeutic target for cancer, and we believe this selectivity may reduce or eliminate toxicities seen with other proteasome inhibitors.”